BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

TFS HealthScience establishes operation in Australia expanding its CRO capabilities to APAC

12 March 2024 | News

The strategic move elevates patient access and innovation for advanced research in Ophthalmology, Dermatology, Neurology, Oncology, and resources.

TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), has expanded into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia.

Through this strategic move, TFS can provide comprehensive clinical research services and support partners with a broader reach to patients, fostering innovative solutions and fostering global collaboration. A vibrant and growing market like APAC presents TFS with the potential to contribute significantly to medical knowledge and patient outcomes.

Dr. Bassem Saleh, Chief Executive Officer at TFS, said "As we extend our footprint into the APAC region, Australia emerges as a strategic focal point for establishing operations in all our business units, including Ophthalmology, Dermatology, Neurology, Oncology, and strategic resourcing. Australia's expanding market aligns perfectly with our vision for growth and innovation. This expansion enables us to better integrate into the APAC region and strengthens our commitment to delivering unparalleled clinical research solutions to our global network."

While the company has previously offered geographical coverage through consultants and partner CROs in the region, this expansion with dedicated operational base, expands TFS's site network and patients' access to clical trials in the region. Starting with Australia, TFS has plans for further growth into other countries in the APAC region, complementing existing partnerships to cater to customer needs globally.

TFS's expansion into the APAC region enhances the company's partnership capabilities, and broadens access to diverse patient populations and cutting-edge technologies and also leverages streamlined regulatory environments for faster, more efficient trial execution.